[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): August 7, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 Peoples Republic of China 86-10-6698-3166 (Former name or former address,]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): August 7, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 Peoples Republic of China 86-10-6698-3166 (Former name or former address,]
[SOHU.COM REPORTS SECOND QUARTER 2012 UNAUDITED FINANCIAL RESULTS Total Revenues were US$256 Million, Up 29% Year-over-Year and 13% Quarter-over-Quarter, Exceeding the High End of Group Guidance by US$6 Million; GAAP Net Income Before Non-Controlling Interest was US$34 Million, Non-GAAP Net Income Before Non-Controlling Interest was US$41 Million; GAAP Fully Diluted EPS of US$0.28, Non-GAAP Fully Diluted EPS of US$0.42 BEIJING,] [Changyou.coms Majority-owned Subsidiary 7Road.com Limited Plans for Confidential Submission of Draft Registration Statement for IPO Beijing, China, August 6, 2012 7Roads primary purposes for conducting the IPO, if commenced, include creating a public market for 7Roads shares and attracting and retaining talented employees by providing them with equity incentives. Safe Harbor Statement 1 About Changyou Changyou.com Limited (NASDAQ: CYOU) is] []
[SOHU.COM REPORTS SECOND QUARTER 2012 UNAUDITED FINANCIAL RESULTS Total Revenues were US$256 Million, Up 29% Year-over-Year and 13% Quarter-over-Quarter, Exceeding the High End of Group Guidance by US$6 Million; GAAP Net Income Before Non-Controlling Interest was US$34 Million, Non-GAAP Net Income Before Non-Controlling Interest was US$41 Million; GAAP Fully Diluted EPS of US$0.28, Non-GAAP Fully Diluted EPS of US$0.42 BEIJING,] [Changyou.coms Majority-owned Subsidiary 7Road.com Limited Plans for Confidential Submission of Draft Registration Statement for IPO Beijing, China, August 6, 2012 7Roads primary purposes for conducting the IPO, if commenced, include creating a public market for 7Roads shares and attracting and retaining talented employees by providing them with equity incentives. Safe Harbor Statement 1 About Changyou Changyou.com Limited (NASDAQ: CYOU) is] []
[CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com 312/867-0848 RESULTS ENTERTAINMENT GAMING ASIA REPORTS SECOND QUARTER 2012 AND PROVIDES MARKET UPDATE - Company Achieves Record Quarterly Gaming Revenue – - Gaming Chip and Plaque Operations Post Solid Revenue Growth and Secure a $2 Million New Order – - Development of Dreamworld Poipet in Cambodia is Underway – Hong Kong –] []
[CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com 312/867-0848 RESULTS ENTERTAINMENT GAMING ASIA REPORTS SECOND QUARTER 2012 AND PROVIDES MARKET UPDATE - Company Achieves Record Quarterly Gaming Revenue – - Gaming Chip and Plaque Operations Post Solid Revenue Growth and Secure a $2 Million New Order – - Development of Dreamworld Poipet in Cambodia is Underway – Hong Kong –] []
[BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after]
[BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after]
[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]
[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]
